Skip to content

Study · Non-randomized trial · n = 23 · 2013

1 result

Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial.

Chrispijn M, Gevers TJ, Hol JC, Monshouwer R, Dekker HM, Drenth JP

Journal of hepatology14 Mar 2013Cited by 61 (Europe PMC)

PMID23499726 (opens in a new tab)DOI10.1016/j.jhep.2013.03.004 (opens in a new tab)PepBankPUB-23499726
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In PLD patients receiving octreotide monotherapy, liver volume decreased by 3.5% (p<0.01).

    In plain wordsIn patients with polycystic liver disease, liver volume decreased during octreotide monotherapy.

    Peptide
    Octreotide
    Outcome
    DecreaseLiver volume
    Study

    n = 23

    Analysis
    Primary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    40 mg every 4 weeks · intramuscular · 48 weeksAs given in this study (human).

    Measurements

    Liver volume change
    −3.5%
    octreotide monotherapy
    P value
    < 0.01
    octreotide monotherapy arm

    Source sentences

    Summary
    Liver volume decreased by 3.5% (p<0.01) in the monotherapy arm,
    4 context sentences
    Summary · context
    Primary outcome was change in liver volume measured with CT-volumetry.
    Summary · context
    We designed a randomized controlled trial that compared 48 weeks of everolimus 2.5 mg daily, combined with octreotide 40 mg intramuscularly every 4 weeks, to octreotide monotherapy.
    Summary · context
    We included PCLD and ADPKD patients.
    Summary · context
    We randomized 44 PLD patients (29 PCLD, 15 ADPKD, 89% female) to treatment with octreotide (n=23) or octreotide-everolimus (n=21).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.